Jaguar Health, Inc. (JAGX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Jaguar Health, Inc. (JAGX) closed at USD 4.18 on 2026-10-14, a change of -99.6 % over the past year, with a market capitalization of USD 8.93M.

Jaguar Health, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Jaguar Health, Inc. key figures

Previous close

USD 4.18 (2026-10-14)

1-year change

-99.6 %

Market cap

USD 8.93M

Enterprise value

USD 14.4M

P/E ratio (trailing)

-0.00

P/E ratio (forward)

-0.81

EPS (trailing)

-4,406.24

EPS (forward)

-5.68

PEG ratio

n/a

Price to book

0.22

Revenue growth

-58.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.02

Employees

47

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Jaguar Health, Inc. and compare it with other stocks.